ALGENTECH, announces the issuance of a key patent in the field of genome editing by the U.S. Patent Office (U.S. patent number...Read More
Cutting edge genome editing booster technologies, organelle transformation and synthetic biology tools for multi-sectorial applications.
Our focus is on the development of nuclease-free methods and design of booster systems to improve efficiency of nuclease-based genome editing technologies with unparalleled efficiency of gene targeting in eukaryotic cells via homologous recombination.
Our proprietary mini-chromosome amplification technology enables the transfer of entire biosynthetic pathways for high expression in plant chloroplasts: units are not integrated in the chloroplast genome, enabling high expression of large polycistrons.
Our unique transport systems enable shuttling nucleic acids into the mitochondria for further expression of genes of interest such as inducers of cytoplasmic male sterility for hybrid seed production.
The company was selected to participate in the Techshare class of 2018/2019. Detailed description of the programme can be found here: https://www.euronext.com/en/news/over-100-new-companies-join-euronext-techshare-programmeRead More
Alexander Sorokin, CEO is at the 2018 BIO World Congress on Industrial Biotechnology held in Philadelphia, July 17-19 2018 (https://www.bio.org/events/bio-world-congress ) The BIO World Congress...Read More